Patient recruitment company for diabetes trials, Medicollect, increases investments and enters UK market.

Copenhagen, Denmark – Medicollect today announced its expansion into UK, increasing its acceptance footprint across the continent. The addition of the British network extends the company’s reach to 3, 4 million diabetes patients.

According to a report produced for the drug company Novartis clinical trials in the United Kingdom cost significantly more than in other European countries, in large because of poor rates of recruitment (source).

“This means that there is an increasing need for innovative and reliable solutions that address market needs,” says Torben Lind, COO at Medicollect. “Our investment in UK will secure that test patients for clinical diabetes trials in United Kingdom will be provided at the same fast, safe and reliable way that Medicollect has serviced the Scandinavian market.

Through collaborating with diabetes stakeholders in UK and Denmark, Medicollect is directly contributing to bringing medical innovation to patients faster and support United Kingdom’s transformation to once more being a strong center for clinical trials.

Want to know more?
Contact Torben Lind

Medicollect expands to UK

There has been great interest in participating in Medicollect’s diabetic panel in Denmark. Therefore Medicollect has decided to establish a panel in England.

In UK the panel will be called “My Life With Diabetes” and the goal is to reach 50,000 British members during 2016.

“It’s clearly a very ambitious goal, but we have set the goal high because our clients demand far more patients in England than in Denmark,” says director Henrik Vincentz.

So far, companies such as SANOFI, NOVO and GSK have shown interest in using Medicollect’s services in UK.

Medicollect gets new CEO

Medicollect was founded in 2012 by Henrik Vincentz and Torben Lind. Since then the company has grown its client base substantially, and the business has proved its sustainability.

In order to strengthen its international profile, the founders have decided to invite a new partner and CEO into the company, and the choice has fallen on Rene Vind Ludwigs, who with his experience in pharma and medical device industry brings strong skills and a comprehensive knowledge of customers’ business processes .

“We are absolutely convinced that we have made the right choice by inviting Rene Ludwig in as a partner”, says the founder, Henrik Vincentz.

Rene Ludwig comes from a position as CSO at Mission Pharma and before that he worked several years as General Manager at GN Resound and at Ambu.

Medicollect’s management now consists of CEO Rene Ludwig, COO Torben Lind and CCO Henrik Vincentz.